Baveno Criteria Safely Identify Patients With Compensated Advanced Chronic Liver Disease Who Can Avoid Variceal Screening Endoscopy: A Diagnostic Test Accuracy Meta-Analysis by Szakács, Zsolt et al.
SYSTEMATIC REVIEW
published: 13 August 2019
doi: 10.3389/fphys.2019.01028
Frontiers in Physiology | www.frontiersin.org 1 August 2019 | Volume 10 | Article 1028
Edited by:
Stephen J. Pandol,
Cedars-Sinai Medical Center,
United States
Reviewed by:
Bogdan Procopet,
Iuliu Hat¸ieganu University of Medicine
and Pharmacy, Romania
Mauro Viganò,
University of Milan, Italy
Meng Yin,
Mayo Clinic, United States
*Correspondence:
Gabriella Pár
par.gabriella@pte.hu
Specialty section:
This article was submitted to
Gastrointestinal Sciences,
a section of the journal
Frontiers in Physiology
Received: 26 April 2019
Accepted: 24 July 2019
Published: 13 August 2019
Citation:
Szakács Z, Ero˝ss B, Soós A, Mátrai P,
Szabó I, Pétervári E, Bajor J,
Farkas N, Hegyi P, Illés A, Solymár M,
Balaskó M, Sarlós P, Szu˝cs Á,
Czimmer J, Vincze Á and Pár G (2019)
Baveno Criteria Safely Identify Patients
With Compensated Advanced Chronic
Liver Disease Who Can Avoid Variceal
Screening Endoscopy: A Diagnostic
Test Accuracy Meta-Analysis.
Front. Physiol. 10:1028.
doi: 10.3389/fphys.2019.01028
Baveno Criteria Safely Identify
Patients With Compensated
Advanced Chronic Liver Disease Who
Can Avoid Variceal Screening
Endoscopy: A Diagnostic Test
Accuracy Meta-Analysis
Zsolt Szakács 1,2, Bálint Ero˝ss 1, Alexandra Soós 1, Péter Mátrai 1,3, Imre Szabó 4,
Erika Pétervári 1, Judit Bajor 4, Nelli Farkas 1,3, Péter Hegyi 1,4,5, Anita Illés 4,
Margit Solymár 1, Márta Balaskó 1, Patrícia Sarlós 4, Ákos Szu˝cs 6, József Czimmer 4,
Áron Vincze 4 and Gabriella Pár 4*
1 Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary, 2 János Szentágothai Research
Center, University of Pécs, Pécs, Hungary, 3 Institute of Bioanalysis, Medical School, University of Pécs, Pécs, Hungary,
4Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary, 5Hungarian
Academy of Sciences-University of Szeged, Momentum Gastroenterology Multidisciplinary Research Group, Budapest,
Hungary, 6 First Department of Surgery, Semmelweis University, Budapest, Hungary
Background: The Baveno VI Consensus Workshop defined criteria (liver stiffness
measured by transient elastography <20 kPa and platelet count >150 × 109 cells/L)
to identify those patients with compensated advanced chronic liver diseases (cACLD)
who are unlikely to have varices needing treatment (VNTs) and can safely avoid variceal
screening endoscopy. This meta-analysis aimed to quantify the safety and efficacy of
these criteria in suspected cACLD with liver stiffness >10 kPa and in compensated
chronic liver diseases (cCLD) irrespective of liver stiffness.
Methods: A systematic search was conducted in nine databases for studies discussed
cACLD or cCLD and tested Baveno criteria against variceal screening endoscopy. The
main safety and efficacy endpoints were missed VNT rate and spared endoscopy
rate (SER), respectively; calculated with the random effect model. Pooled sensitivity,
specificity, and area under the curve (AUC) were calculated with the hierarchical summary
receiver operating characteristic model. For all outcome measures, 95% confidence
intervals were computed. Heterogeneity was tested with I2-statistics.
Results: The search yielded 13 studies including 4,464 patients which reported on
suspected cACLD. Pooled missed VNT rate was 0.3% (0.1–0.6%; I2 = 45.5%), pooled
SER was 32.8% (24.8–41.4%; I2 = 97.0%). Sensitivity, specificity, and AUC of
Baveno criteria were 97% (95–98%), 41% (27–57%), and 96% (94–97%), respectively.
In the subgroups of cACLD from hepatitis C and B viruses, non-alcoholic fatty
liver disease/steatohepatitis, or alcohol, missed VNT rates were 0.0% (0.0–0.3%),
1.2% (0.4–2.2%), 0.0% (0.0–1.3%), or 0.0% (0.0–0.4%), while SERs were 24.2%
(20.5–28.1%), 24.9% (21.7–28.4%), 38.6% (10.9–70.8%), or 27.0% (16.9–38.4%),
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respectively. If we expanded the study population to cCLD, 27 studies included 7,534
patients. Missed VNT rate was 0.2% (0.1–0.5%; I2 = 39.8%) with a SER of 30.5% (25.2–
36.2%; I2 = 96.1%) while Se, Sp, and AUC were 97% (93–99%), 35% (27–44%), and
80% (77–84%), respectively.
Conclusions: The application of Baveno criteria significantly reduces the number of
unnecessary variceal screening endoscopies while being safe: cACLD patients with liver
stiffness <20 kPa and platelet count > 150 × 109 cells/L carry a very low chance (i.e.,
0.3%) of having VNTs. The criteria preserve low missed VNT rate with lower diagnostic
performance among cCLD patients.
Keywords: fibroscan, platelets, variceal bleeding prediction, high-risk varices, diagnostic accuracy
INTRODUCTION
Liver cirrhosis is a significant cause of global health burden and
responsible for more than one million deaths per year worldwide
(Mokdad et al., 2014; Scaglione et al., 2015). One of the leading
causes of liver-related fatalities is variceal bleeding (Garbuzenko,
2016). Esophageal varices are present in 30–40% of patients with
compensated cirrhosis, while their prevalence reaches even 85%
in patients with decompensated cirrhosis (Zipprich et al., 2012).
Rationale
Prognosis of compensated chronic liver diseases (cCLD) with
esophageal varices is far worse compared to that without them
(Zipprich et al., 2012). The risk of variceal bleeding increases with
advanced liver disease, with decompensation of the liver disease,
with larger size of varices, and with the presence of red signs
(North Italian Endoscopic Club for the Study and Treatment of
Esophageal Varices, 1988). Early detection of varices and their
treatment successfully reduce the risk of bleeding and increases
life expectancy (De Franchis, 2015).
The gold standard of detection and grading of esophageal
varices has remained esophagogastroduodenoscopy (EGD) (De
Franchis, 2015). However, EGDs negative for varices needing
treatment (VNTs) account for more than two-thirds of the
cases, which number imposes a potentially avoidable economic
burden on the healthcare system (Maurice et al., 2016; Augustin
et al., 2017; Colecchia et al., 2018). Not to mention the risks
and inconvenience of the procedure, leading to anxiety and
potentially resulting in poor adherence (Ersoz et al., 2010; Simon
et al., 2017). In the light of these drawbacks, the need for a
non-invasive substitute for EGD is evident.
The BavenoVI ConsensusWorkshop (2015) defined an entity,
compensated advanced chronic liver disease (cACLD), which
carries the risk of clinically significant portal hypertension (De
Abbreviations: ALD, alcoholic liver disease; AUC, area under the curve; cACLD,
compensated advanced chronic liver disease; cCLD, compensated advanced
chronic liver disease; CI, confidence interval; EGD, esophagogastroduodenoscopy;
GRADE, Grading of Recommendations Assessment, Development and
Evaluation; HBV, hepatitis B virus; HCV, hepatitis C virus; LS, liver stiffness;
NAFLD/NASH, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis;
QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2; Se, sensitivity;
SER, spared endoscopy rate; Sp, specificity; VNTs, varices needing treatment.
Franchis, 2015). To reduce the number of endoscopies, the
Baveno VI recommendation allows that cACLD patients with a
liver stiffness (LS) measured by transient elastography <20 kPa
and a platelet count > 150 × 109 cells/L (Baveno criteria) can
avoid screening EGD. If both criteria are met, patients are at
low risk (<5%) of having VNTs (De Franchis, 2015). In general,
Baveno criteria aimed to rule out (and not to rule in) VNTs.
One year later, a meta-analysis summarized how LS and
platelet count predict the risk of esophageal varices and varices
at risk of bleeding (Marot et al., 2017). However, this meta-
analysis was limited due to the available evidence because mostly
conference abstracts were included and the low number of studies
did not allow the restriction of study population to cACLD,
nor to different etiologies. Since then, a large body of evidence
has accumulated based on several high-quality diagnostic test
accuracy studies (Augustin et al., 2017; Jangouk et al., 2017; Llop
et al., 2017; Silva et al., 2017; Sousa et al., 2017; Bae et al., 2018;
Bellan et al., 2018; Colecchia et al., 2018; Lee et al., 2018; Petta
et al., 2018; Stanislas et al., 2018; Thabut et al., 2019; Tosetti et al.,
2019a).
Objectives and Research Question
The aim of this meta-analysis was to provide an up-to-date
summary on the safety and efficacy of Baveno criteria (LS < 20
kPa and platelet count > 150 × 109 cells/L), focusing on cACLD
and cCLD of various causes.
METHODS
Study Design
We conducted and reported this work in accordance with
the Preferred Reporting Items for a Systematic Review andMeta-
analysis of Diagnostic Test Accuracy Studies (2018) (McInnes
et al., 2018).
Participants, Interventions, Comparators
The population of interest included adult cases of cCLD. The
diagnostic accuracy for predicting VNTs of Baveno criteria was
compared to that of the standard EGD.
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Systematic Review Protocol
The protocol of this meta-analysis was registered in advance
in the PROSPERO database under the registration number
of CRD42018096146.
Search Strategy
We performed a systematic search in nine medical databases
(MEDLINE via PubMed, EMBASE via Ovid, CENTRAL, Web of
Science, Scopus, WHOGlobal Health Library, ScieELO, LILACS,
and ClinicalTrials.gov) from 1st January 2003, when transient
elastography (Fibroscan R©) became available in Europe, up to the
end of May 2019 with the free-text terms liver AND (stiffness OR
elastography OR sonoelastography OR fibroscan OR platelet OR
thrombocyte OR BAVENO) AND (varices OR varix OR “portal
hypertension”). These were combined with Medical Subject
Headings including liver, hypertension portal; blood platelets,
elasticity imaging techniques, varicose veins. Apart from the time
restriction, we did not apply any filters to the search.
As additional data sources, we went through the reference lists
of relevant included and excluded records with hand search and
sought for citing articles with Google Scholar.
Study Selection and Data Extraction
Eligible diagnostic accuracy studies discussed adult cases of
cCLD and tested the diagnostic accuracy of Baveno criteria
(i.e., the index test) against EGD (i.e., the reference standard)
in the detection of VNTs. The primary safety and efficacy
outcomes were missed VNT rate and spared endoscopy rate
(SER), respectively. Secondary outcomes included diagnostic
accuracy metrics, such as sensitivity, specificity, and area under
the curve (AUC) of Baveno criteria for detecting VNTs.
cCLD was defined as a chronic liver disease of Child-
Pugh A or B without obvious signs of parenchymal or portal
FIGURE 1 | Flowchart of the meta-analysis.
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TABLE 1 | Characteristics of the studies included.
References Setting Population Etiology No. of
patients
Prevalence
of VNTs
TP FP FN TN
Arriero et al., 2017* Spain, single-center
(retrospective; 2013
January−2016 April)
cACLD (LS > 12
kPa)
Viral: 52.4%,
other: 47.6%
234 5% 12 182 0 40
Augustin et al., 2017 Spain, France, Romania, and
Canada, multi-center
(retrospective; 2014–2015)
cACLD (LS ≥ 10
kPa)
HCV 117 7% 9 79 0 29
Bae et al., 2018 Korea, single-center
(retrospective; 2012 July−2016
December)
cACLD (LS ≥ 10
kPa)
HBV: 58.9%,
HCV: 16.3%,
ALD: 18.8%,
NAFLD: 6%
282 20% 52 152 3 75
Bai et al., 2018* New Zealand, single-center (not
reported)
cACLD (LS ≥ 10
kPa)
HCV: 40%,
NAFLD: 24.9%,
HBV: 15.6%
205 10% 20 131 0 54
Bellan et al., 2018 Italy (not reported) cCLD (LS ≥ 6
kPa)
HCV 147 11% 16 97 1 33
Chang et al., 2016* Singapore, single-center
(retrospective; 2006–2012)
cACLD (LS > 12
kPa)
Viral: 55%, other:
45%
173 8% 11 128 3 31
Colecchia et al.,
2018
Italy and Switzerland,
three-center (retrospective;
2012–2016 and prospective;
2017 September−2018
February)
cACLD (LS ≥ 10
kPa)
HCV: 76.6%,
HBV: 5.8%, ALD:
8.8%,
NAFLD/NASH:
3.1%,
autoimmune:
0.5%,
miscellaneous:
5.2%
613 19% 114 378 1 120
Jangouk et al., 2017 USA and Italy, double-center
(retrospective; 2010 May−2016
April and 2014 February−2016
April)
cACLD (LS ≥10
kPa)
HCV: 70.6%,
ALD: 12.5%,
NAFLD: 7.7%,
other: 9.2%
262 12% 31 174 0 57
Kew et al., 2018* Singapore (retrospective;
2013–2015)
cACLD (LS ≥ 10
kPa)
HBV: 30%,
NASH: 24.4%,
HCV: 17.7%,
164 18% 28 86 2 48
Lee et al., 2018 Korea; 4-center (retrospective;
2014 January−2017 December)
cACLD (LS ≥ 10
kPa)
HBV: 39.7%,
HCV: 12.1%,
ALD: 29.2%,
other: 19.0%
1218 20% 243 662 6 307
Levick et al., 2018* UK (not reported) cACLD ALD: 35%,
NAFLD: 22%,
viral: 16%, other:
27%
45 20% 9 29 0 7
Llop et al., 2017 Spain, single-center
(retrospective; 2013
September−2015 September)
cACLD (LS ≥ 10
kPa)
HCV: 85.1%,
HCV and ALD:
3.1%, HBV:
3.7%,
autoimmune:
3.1%, NASH:
3.7%, other:
1.2%
161 Not
reported
Not
reported
Not
reported
0 54
Maurice et al., 2016 UK, double-center (retrospective;
2006 November−2015
September)
cACLD (LS ≥ 10
kPa)
HCV: 55%,
HBV/HDV: 8%,
ALD: 13%,
NAFLD: 14%,
other: 11%
310 5% 13 195 2 100
Matsui et al., 2018 Japan; double-center
(retrospective; 2013 April−2016
December)
cCLD NAFLD: 39%,
HCV: 39%, ALD:
9%, HBV: 6%;
PBC: 6%
384 3% 46 104 2 223
(Continued)
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TABLE 1 | Continued
References Setting Population Etiology No. of
patients
Prevalence
of VNTs
TP FP FN TN
McDowell et al.,
2018*
UK; single-center (retrospective) cCLD Not reported 82 Not
reported
Not
reported
Not
reported
0 24
Moctezuma-
Velazquez et al.,
2019
UK, Spain, Canada, Switzerland;
4-center (retrospective; 2009
March−2017 December)
cACLD (LS > 10
kPa)
PBC: 65%, PSC:
35%
227 13% 30 115 0 82
Ng et al., 2018* Australia; single-center
(retrospective; 2011 May−2016
June)
cACLD (LS > 12
kPa)
NAFLD: 60%,
ALD: 40%
85 8% 7 53 0 25
Pawar et al., 2018* India (prospective) cACLD (LS > 10
kPa)
NASH: 47.72%,
HBV: 20.45%,
ALD: 13.63%,
others: 11,36%,
HCV: 5.68%,
HBV/HCV: 1.13%
88 31% 24 6 3 55
Perazzo et al., 2015 Brazil (prospective) cACLD Not reported 97 14% 14 62 0 21
Perez Ferrer et al.,
2017*
Spain, single-center (not
reported)
cACLD (LS > 15
kPa)
HCV 32 16% 1 14 4 13
Petta et al., 2018 Italy, France, Canada, UK,
Hong Kong, and Switzerland,
ten-center (retrospective)
cACLD (LS > 11
kPa or >11.5
kPa)
NAFLD 639 11% 67 338 6 228
Silva et al., 2017 Portugal, single-center
(retrospective; 2009
September−2015 October)
cACLD (LS > 12
kPa)
HCV: 78.4%,
ALD: 8.2%, HBV:
3.1%, biliary:
3.1%, other:
7.2%
97 14% 14 72 0 11
Sousa et al., 2017 Portugal, single-center
(retrospective; 2013
January−2015 December)
cCLD HCV: 66%,
HCV/HIV: 16%,
ALD: 12%, HBV:
4%, other: 5%
104 9% 9 47 0 48
Stanislas et al., 2018 Côte d’Ivoire, double-center
(prospective; 2016
January−2016 July)
cACLD (LS ≥ 11
kPa)
HBV 60 33% 20 28 0 12
Tadkalkar et al.,
2018*
India (2016 September−2017
August)
cACLD (LS > 10
kPa)
HBV, HCV,
NASH, ALD
375 22% 80 29 4 262
Thabut et al., 2019 France; 35-center (retrospective;
until 2015 December)
cCLD HCV: 81%, HBV:
16.6%,
HCV/HBV: 2.4%
891 8% 69 601 3 298
Tosetti et al., 2019a Italy; single-center (retrospective;
2010 February−2016 January)
cACLD (LS ≥ 10
kPa)
HCV: 69%, HBV:
10%, NASH:
15%, ALD: 6%
442 7% 31 325 0 86
Tosetti et al., 2019b* Italy (retrospective) cACLD (LS ≥ 10
kPa)
HCV 192 4% 8 141 0 43
*Conference abstracts. ALD, alcoholic liver disease; cACLD, compensated advanced chronic liver disease; cCLD, compensated chronic liver disease; FN, false negative; FP, false
positive; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HIV, human immunodeficiency virus; LS, liver stiffness; NAFLD, non-alcoholic fatty liver disease; NASH,
non-alcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerotizing cholangitis; TN, true negative; TP, true positive; US, ultrasound; VNT, varices needing treatment.
decompensation. Within cCLD, we investigated two subgroups
of suspected cALCD: one contained studies with LS > 10 kPa
in accordance with Baveno VI recommendations, the other
contained studies using an LS cut-off between 10 and 15 kPa.
VNTs were defined as per the criteria within the individual
studies (medium/large esophageal varices or the presence of red
signs on varices with any grade).
Records yielded by the search were combined in a reference
manager software (EndNote X7.4, Clarivate Analytics,
Philadelphia, PA, US). Our selection and data collection
process were designed according to the Cochrane Handbook
for Systematic Reviews (Higgins and Green, 2011). After
removing overlaps between databases and duplicate references,
the remaining records were subjected a standard three-step
selection (by title, abstract, and full-text) by two review authors
in duplicate, with third-party arbitration resolving discrepancies
after each step. Eligible original studies (including conference
abstracts, journal articles, letters, comments, and replies) were
subjected to data collection onto pre-defined Excel sheets by the
same review authors included in selection. Discrepancies were
resolved by consensus. Technical details of data collection are
described in Supplementary Appendix 1.
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FIGURE 2 | Risk of bias and applicability assessment with QUADAS-2. Domains A-D cover patient selection, index test (i.e., the Baveno criteria), reference standard
(i.e., esophagoscopy), and flow and timing, respectively. All domains contain sets of questions concerning risk of bias (columns A1–A3, B1–B2, C1–C2, and D1–D3 in
the figure), answered with yes, no, or uncertain denoted by a green tick, a red x, or a blue question mark, respectively; summarized as an overall risk of bias for each
domain (columns RoB in the figure; green tick, red x, and blue question mark represent low, high, and uncertain risk of bias). Domains A-C include an applicability item
each; green tick, red x, and blue question mark represent low, high, and uncertain concerns regarding applicability, respectively. For further details of the assessment,
see Supplementary Appendix 2.
FIGURE 3 | Missed VNT rate and spared endoscopy rate with the Baveno criteria among patients with compensated advanced chronic liver disease. cACLD,
compensated advanced chronic liver disease; CI, confidence interval; SE, spared endoscopies; SER, spared endoscopy rate; VNT, varices needing treatment.
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Risk of Bias and Applicability Assessment
Two review authors assessed risk of bias in and applicability
of the individual studies with the Quality Assessment of
Diagnostic Accuracy Studies-2 (QUADAS-2) (Whiting
et al., 2011). The topic-tailored items are presented in
Supplementary Appendix 2.
Quality of Evidence
The Grading of Recommendations Assessment, Development
and Evaluation (GRADE) was used for estimating the quality
of evidence of safety and efficacy endpoints (Guyatt et al.,
2008). Since upgrading items are not validated to diagnostic test
accuracy meta-analyses, we decided to assess grade of evidence
along five downgrading items, that is, risk of bias, indirectness,
inconsistency, imprecision, and publication bias.
Data Analysis
We constructed 2 × 2 diagnostic tables from the data
extracted. Tables consist of true positive, true negative, false
positive, and false negative cells containing the number of
corresponding patients. Reference and index tests were chosen
to be EGD and Baveno criteria (cut-off for every study:
a platelet count > 150 × 109 cells/L and an LS < 20
kPa), respectively. Missed VNT rate [false negative cases/total
number of patients] and SER [(true negative + false negative
cases)/total number of patients] were calculated by using the
random effects model with the Der-Simonian Lard estimation
(Cales et al., 2018). Sensitivity (Se), specificity (Sp), and AUC
were calculated by using the hierarchical summary receiver
operating characteristic (HSROC) model. 95% confidence
intervals (CIs) and predictive intervals (PIs) were used in
all analyses.
Heterogeneity was examined with I2- and chi2-test and
explored with subgroup analysis and metaregression. Pre-
planned subgroup analyses were carried out for patients with
suspected cACLD (with an LS cut-off of 10 kPa and between 10
and 15 kPa), etiology (hepatitis B and C viruses [HBV and HCV,
respectively], non-alcoholic fatty liver disease/non-alcoholic
steatohepatitis [NAFLD/NASH], and alcoholic liver disease
[ALD]), publication type (journal article vs. conference abstract),
and prospectivity of the study. Meta-regression was performed
to analyze the effects of 14 variables on missed VNT rate
and SER.
Egger’s test was performed and funnel plots were constructed
to test small-study. If p≥ 0.1, publication bias is unlikely to occur
in the sample.
Further details are reported in Supplementary Appendix 1.
RESULTS
Study Selection and Characteristics
Figure 1 displays the flow of work. The search yielded an
overall 11,016 records in databases (MEDLINE: 1,410, EMBASE:
4,738, CENTRAL: 212, Web of Science: 1,713, Scopus: 2,708,
WHO Global Health Library: 166, ScieELO: 24, LILACS: 26,
and ClinicalTrials.gov: 19). After careful selection, 44 potentially
eligible studies were subjected for inclusion, 16 of which (15
conference abstracts and one journal article) were excluded due
to overlapping study populations (Supplementary Appendix 3).
For the same reason, only subgroups of two multicenter studies
(Augustin et al., 2017; Petta et al., 2018) were eligible for inclusion
(Supplementary Appendix 3). Finally, 17 journal articles and
11 conference abstracts were included (Perazzo et al., 2015;
Chang et al., 2016; Maurice et al., 2016; Arriero et al., 2017;
Augustin et al., 2017; Jangouk et al., 2017; Llop et al., 2017;
Perez Ferrer et al., 2017; Silva et al., 2017; Sousa et al., 2017;
Bae et al., 2018; Bai et al., 2018; Bellan et al., 2018; Cales
et al., 2018; Colecchia et al., 2018; Kew et al., 2018; Lee
et al., 2018; Levick et al., 2018; Matsui et al., 2018; McDowell
et al., 2018; Ng et al., 2018; Pawar et al., 2018; Petta et al.,
2018; Stanislas et al., 2018; Tadkalkar et al., 2018; Moctezuma-
Velazquez et al., 2019; Thabut et al., 2019; Tosetti et al., 2019a,b).
All the 28 studies provided data on missed VNT rate and
SER but one conference abstract (Tosetti et al., 2019b) was
used only in subgroup analysis by etiology due to overlapping
study population with a full-text article in the main analysis
(Tosetti et al., 2019a). A total of 26 studies were eligible for
HSROC analysis. Table 1 summarizes the characteristics of the
FIGURE 4 | Summary receiver operating characteristic (SROC) curves. (A) Compensated advanced chronic liver disease (with an LS cut-off of 10 kPa). (B)
Compensated advanced chronic liver disease (with an LS cut-off between 10 and 15 kPa). (C) Compensated chronic liver disease. AUC, area under the curve; LS,
liver stiffness; SENS, sensitivity; SPEC, specificity.
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studies included. The most common underlying pathologies
were HCV and alcohol. Prevalence of VNTs ranged from
4 to 33% in study populations suggesting a wide range of
disease severity.
Risk of Bias and Applicability
Risk of bias and applicability of the studies included is
summarized in Figure 2.
Performance of Baveno Criteria Among
cACLD Patients With an LS Cut-Off of 10
kPa
In the 13 studies which discussed suspected cACLD (with an
LS cut-off of 10 kPa), 4,464 patients were included. Missed
VNT rate was 0.3% [CI 0.1–0.6% (I2 = 45.5%, p = 0.037)]
with a SER of 32.8% [CI 24.8–41.4% (I2 = 97%, p <
0.001)] (Figure 3). Se, Sp, and AUC of Baveno criteria were
97% [CI 95–98%], 41% [CI 27–57%], and 96% [CI 94–97%],
respectively (Figure 4A).
When we restricted the analysis to cACLD with HCV,
HBV, NAFLD/NASH, and ALD, missed VNT rates were
0.0% [CI 0.0–0.3%], 1.2% [CI 0.4–2.2%], 0.0% [CI 0.0–1.3%],
and 0.0% [CI 0.0–0.4%], while SERs were 24.2% [CI 20.5–
28.1%], 24.9% [CI 21.7–28.4%], 38.6% [CI 10.9–70.8%], and
27.0% [CI 16.9–38.4%], respectively (Figure 5). The number
of studies did not allow us to calculate other diagnostic
metrics reliably.
Normalized frequencies (Se: 97% and Sp: 41%) assuming a
prevalence of VNTs to be 5, 10, 15, 20, and 25% are reported in
Table 2.
FIGURE 5 | Missed VNT rate and spared endoscopy rate with the Baveno criteria among patients with compensated advanced chronic liver disease of various
etiologies. We failed to investigate heterogeneity and calculate predictive intervals for the subgroups of HBV and NASH/NAFLD due to the low number of studies
included. ALD, alcoholic liver disease; cACLD, compensated advanced chronic liver disease; CI, confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus;
NASH/NAFLD, non-alcoholic steatohepatitis/non-alcoholic fatty liver disease; SE, spared endoscopies; SER, spared endoscopy rate; VNT, varices needing treatment.
TABLE 2 | Normalized frequencies for a sensitivity of 97% and a specificity of 43%.
In a sample population of 1,000 subjects with cACLD (with an LS cut-off 10 kPa)
Prevalence of VNTs 5% 10% 15% 20% 25%
VNTs (n) 50 100 150 200 250
Missed VNTs (n) 1.5 3 4.5 6 7.5
Still unnecessary endoscopies (n) 560.5 531 501.5 472 442.5
Spared endoscopies (n) 391 372 353 334 315
cACLD, compensated advanced chronic liver disease; LS, liver stiffness; VNTs, varices needing treatment.
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Performance of Baveno Criteria Among
cACLD Patients With an LS Cut-Off
Between 10 and 15 kPa
In the 7 studies which discussed suspected cACLD (with an LS
cut-off between 10 and 15 kPa), missed VNT rate was 0.5% [CI
0.0–1.8% (I2 = 65.1%, p= 0.009)] with a SER of 25.1% [CI 16.5–
34.9% (I2 = 91.6%, p < 0.001)] (Figure 3). Se, Sp, and AUC
of Baveno criteria were 97% [CI 62–100%], 27% [CI 19–37%],
and 43% [CI 38–47%], respectively (Figure 4B). The number of
studies did not allow us to perform subgroup analysis by etiology.
Performance of Baveno Criteria Among
cCLD Patients
If we expanded the coverage of the meta-analyis to patients with
cCLD (irrespective of LS), 27 studies reported on 7,534 cCLD
patients. Missed VNT rate was 0.2% [CI 0.1–0.5% (I2 = 39.8%,
p = 0.019)] with a SER of 30.5% [CI 25.2–36.2% (I2 = 96.1%, p
< 0.001)] (Figure 6). Se, Sp, and AUC of Baveno criteria were
97% [CI 93–99%], 35% [CI 27–44%], and 80% [CI 77–84%],
respectively (Figure 4C).
When we restricted the analysis to cCLD from HCV, HBV,
NAFLD/NASH, and ALD, missed VNT rates were 0.2% [CI 0.0–
1.4%], 0.0% [CI 0.0–0.2%], 0.1% [CI 0.0–0.7%], and 0.0% [CI
0.0–0.2%], while SERs were 30.0% [CI 22.7–37.8%], 23.3% [CI
18.1–28.9%], 34.4% [CI 22.5–47.3%], and 26.3% [CI 18.7–34.7%],
respectively (Figure 7). Se, Sp, and AUC of Baveno criteria were
99% [CI 57–100%], 32% [CI 25–41%], and 47% [CI 43–51%] for
cCLD from HCV and 99% [CI 82–100%], 32% [CI 25–40%], and
82% [CI 78–85%] for cCLD from ALD, respectively. The number
of studies did not allow us to calculate other diagnostic metrics
reliably for cCLD from NASH/NAFLD or HBV.
Exploration of Statistical Heterogeneity
Effects of subgroups by etiology are discussed above (Figures 5,
7). When we removed conference abstracts from the analysis,
the heterogeneity reduced (I2 = 0.0%, p = 0.564) while missed
VNT rate was maintained at 0.2% [CI 0.1–0.4%]. This effect was
not manifested in efficacy, where heterogeneity persisted at I2
= 94.7%, p < 0.001 with slightly reduced SER (28.2% [CI 23.2–
33.6%]). The separate analysis of the four prospective studies did
not reduce heterogeneity.
On metaregression, none of the potential modifiers of Baveno
criteria had a significant effect on missed VNT rate. Interestingly,
there was a significant positive correlation of SER with age,
albumin level, and the proportion of NAFLD/NASH in the study
population, while a significant negative correlation with the
proportion of viral liver disease in the study population and with
the alanine and aspartate aminotransferase levels (Table 3).
Publication Bias
Neither the Egger’s tests nor the visual assessment of the
symmetry of the funnel plots indicated the presence of
publication bias (Supplementary Appendix 4).
FIGURE 6 | Missed VNT rate and spared endoscopy rate with the Baveno criteria among patients with compensated chronic liver disease. CI, confidence interval; SE,
spared endoscopies; SER, spared endoscopy rate; VNT, varices needing treatment.
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FIGURE 7 | Missed VNT rate and spared endoscopy rate with the Baveno criteria among patients with compensated chronic liver disease of various etiologies. ALD,
alcoholic liver disease; CI, confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus; NASH/NAFLD, non-alcoholic steatohepatitis/non-alcoholic fatty liver
disease; SE, spared endoscopies; SER, spared endoscopy rate; VNT, varices needing treatment.
DISCUSSION
A large number of studies focused on how safely and effectively
Baveno criteria rule out VNTs in cACLD, so we performed this
meta-analysis to investigate diagnostic metrics of Baveno criteria
regarding VNTs. Our meta-analysis testifies that, though Baveno
criteria safely rule out VNTs in cACLD (missed VNT rate: 0.3%),
SER remains still relatively low (32.8%). Based on our results,
substantially <5% of VNTs would have been missed by using the
criteria (De Franchis, 2015). In other words, diagnostic metrics
of Baveno criteria proved to be excellent in cACLD (LS <10
kPa) (Figure 4A). However, the criteria are limited: although they
seem to be adequate for ruling out VNTs, a large number of EGD
is still unnecessary (Table 2). GRADE approach is summarized in
Table 4.
A previous meta-analysis focused on partly overlapping
questions (Marot et al., 2017). Its available evidence was humble:
only two out of ten reports were fully published articles,
other data were collected from conference material including
personal communication (“gray literature”). In contrast, our
study focusing strictly on VNTs included 28 reports, of them 17
were journal articles (“white,” peer-reviewed literature) (Table 1).
In addition, we had available data to investigate the safety
and efficacy of Baveno criteria in cCLD and cACLD from
different etiologies (Figures 5, 7). To preserve transparency,
we decided not to extract gray data from the previous meta-
analysis if the original record with a full dataset was not
available online.
While the previous meta-analysis found a negative predictive
value of 96.9% for VNTs, the increased sample size and the higher
quality of studies validating Baveno criteria resulted in a missed
VNT rate of 0.3% among cACLD with LS > 10 kPa and 0.2%
among cCLD irrespective of LS. Results were consistent in the
subgroups defined by etiology of the liver disease. The exclusion
of conference abstracts homogenized the data.
Results of meta-regressions were surprising (Table 3). While
the safety endpoint (i.e., missed VNT rate) remained unaffected,
the efficacy endpoint (i.e., SER) showed a significant correlation
with several variables. In viral liver disease, elastography may
overestimate LS; thereby, leading to the negative correlation
of the proportion of viral liver disease, alanine, and aspartate
amino transferases with SER. The positive correlation between
SER and albumin level may reflect the severity of the liver
disease because, as proved by calculating normalized frequencies
(Table 2), the higher the proportion of VNTs in a population, the
less effective Baveno criteria are. However, we cannot explain the
positive correlation between the proportion of NAFLD/NASH
and SER. Indeed, the criteria work well in this subgroup as well.
We must be cautious when interpreting these results, since a
metaregression from population-level data is strongly limited.
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TABLE 3 | Metaregression analyses with the potential modifiers of missed VNT
rate and spared endoscopy rate.
Explanatory
variable
No. of
observations
Coefficient (95% CI) P-value
Missed VNT rate
Age (year) 16 0.001 (−0.009 to 0.095) 0.981
Albumin (g/dL) 14 0.013 (−0.166 to 0.168) 0.987
Alcoholic etiology
(% of total)
19 0.000 (−0.002 to 0.003) 0.956
ALT (U/l) 14 −0.001 (−0.012 to 0.011) 0.919
AST (U/l) 13 0.000 (−0.028 to 0.028) 0.984
Bilirubin (mg/dL) 13 −0.034 (−0.135 to 0.128) 0.956
BMI (kg/m2) 14 −0.010 (−0.238 to 0.219) 0.929
Creatinine
(mg/dL)
12 −0.007 (−0.330 to 0.317) 0.992
Gender (male%) 20 0.000 (−0.003 to 0.003) 0.959
INR 12 −0.043 (−0.908 to 0.823) 0.915
Liver stiffness
(kPa)
21 −0.001 (−0.004 to 0.040) 0.952
MELD score 10 −0.017 (−0.040 to 0.370) 0.922
NAFLD/NASH (%
of total)
17 0.000 (−0.002 to 0.002) 0.889
Platelet count
(109 cells/L)
21 0.000 (−0.013 to 0.012) 0.961
Viral etiology (%
of total)
22 0.000 (−0.001 to 0.001) 0.935
SER
Age (year) 16 0.019 (0.012 to 0.037) 0.038*
Albumin (g/dL) 14 0.336 (0.004 to 0.667) 0.048*
Alcoholic etiology
(% of total)
19 0.015 (−0.006 to 0.009) 0.701
ALT (U/l) 14 −0.003 (−0.005 to −0.001) 0.047*
AST (U/l) 13 −0.006 (−0.010 to −0.001) 0.028*
Bilirubin (mg/dL) 13 0.084 (−0.058 to 0.225) 0.219
BMI (kg/m2) 14 −0.038 (−0.083 to 0.007) 0.093
Creatinine
(mg/dL)
Conditions of the analysis were not met
Gender (male%) 20 −0.002 (−0.007 to 0.004) 0.554
INR 12 −0.753 (−1.831 to 0.325) 0.151
Liver stiffness
(kPa)
21 −0.008 (−0.018 to 0.003) 0.134
MELD score 10 −0.013 (−0.059 to 0.033) 0.541
NAFLD/NASH (%
of total)
17 0.005 (0.001 to 0.009) 0.001*
Platelet count
(109 cells/L)
21 0.003 (-0.001 to 0.005) 0.050
Viral etiology (%
of total)
22 −0.002 (−0.004 to −0.000) 0.046*
*Indicates a probability value (p) < 0.05. AST, aspartate aminotransferase; ALT, alanine
aminotransferase; BMI, body mass index; CI, confidence interval; INR, international
normalized ratio; MELD, model for end-stage liver disease; NASH/NAFLD, non-alcoholic
steatohepatitis/non-alcoholic fatty liver disease; VNT, varices needing treatment.
Our meta-analysis has several strengths, most importantly
the rigorous methodology. We performed a systematic search
followed by reproducible selection and data extraction. Risk of
bias assessment was performed with the use of the recent gold
standard methodology, the QUADAS-2 (Whiting et al., 2011).
Meta-analytical calculations were performed by experienced
biostatisticians. The grade of evidence of our statements was
quantified with the GRADE approach (Table 4; Guyatt et al.,
2008). Small-study effect was unlikely to distort our results, as
revealed by the symmetry of funnel plots with the confirmatory
results of the Egger’s tests (Supplementary Appendix 4).
Although there was substantial statistical heterogeneity in
some analyses, we identified several potential confounding
factors.When we set up subgroups by etiology of the liver disease,
heterogeneity reduced to 0% for missed VNT rate in cCLD
from HBV, NAFLD/NASH, and HCV and in cACLD (LS <10
kPa) from HCV and ALD. However, we have to acknowledge
that if less than four studies were included, the statistical
model did not allow the computation of I2 values (Figure 5).
About one-third of the papers included were conference
abstracts; elimination of these from the analysis reduced
the heterogeneity substantially while it did not change the
main associations. Metaregression demonstrated the potential
modifying effects of frequently measured clinical variables as well
(Table 3). However, these results should rather be considered
as explanatory ones, since none of the studies included
analyzed the effect of continuous variables on missed VNT rate
and SER.
Risk of bias and inapplicability may distort our results as
demonstrated by the QUADAS-2 (Figure 2). Since most studies
were retrospective, blinding of the operators, and endoscopists
was probably not introduced. The time elapsed between the
EGD and transient elastography was not reported in few studies,
while that between EGD and the measurement of platelet
count was lacking in most studies. Ideally, LS and platelet
count should be measured at the same time than variceal
assessment; however, studies were permissive because 3–12
months difference between measurements were almost always
tolerated. Four studies reported the use of M-probes exclusively,
while only five studies reported the use of M- and XL-probes
depending on nutritional status. This raises concerns about the
number of unsuccessful LS measurements, imposing the risk of
selection bias (Ji et al., 2014). Poor reporting of methodological
details, particularly on elastography, was a common issue as well
(Figure 5).
Elastography has its own drawbacks, as well. In routine
clinical practice, unreliable results are obtained in nearly one
in five cases, which are usually associated with obesity and
are dependent on the operators’ experience (Castera et al.,
2010). False positivity is often associated with acute hepatitis,
extra-hepatic cholestasis, liver congestion, prior food intake,
and excessive alcohol intake (European Association for Study
of Liver Asociacion Latinoamericana para el Estudio del
Higado, 2015). Accordingly, inclusion and exclusion criteria
involving these factors mildly varied across studies, restricting
the applicability of our findings. The Baveno VI Consensus
Workshop recommended that transient elastography should
be performed in fasting condition with attention to alanine
transaminase flares and should be repeated on two different days
to avoid misclassification (De Franchis, 2015).
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TABLE 4 | Summary of findings table.
Population: patients suffering from cACLD (with an LS cut-off of 10 kPa)
Index test: Baveno VI criteria for ruling out VNTs (LS < 20 kPa and platelet count >150 × 109 cells/L)
Reference standard: Variceal screening endoscopy
Outcomes: Safety (i.e., missed VNT rate) and efficacy (i.e., SER)
Outcomes No. of studies
(patients)
Point estimate (95%
confidence interval)
Importance Quality of evidence Comments
Missed VNT rate 13
(4,464)
0.3%
0.1–0.6%
Critical •••◦ moderate Downgraded for risk of bias
SER 13
(4,464)
32.8%
24.8–41.4%
Important ••◦◦ low Downgraded for risk of bias and inconsistency
cACLD, compensated advanced chronic liver disease; LS, liver stiffness; SER, spared endoscopy rate; VNTs, varices needing treatment.
Combining the criteria with spleen stiffness measurements
(with a cut-off of spleen stiffness ≤ 46 kPa) resulted in a SER of
43.8% with <5% missed VNT rate (Colecchia et al., 2018). The
combination seems attractive because no further instruments
(such as abdominal ultrasound) is required. Nevertheless, we
must be aware of its limitation, the high rate of unsuccessful
spleen stiffness measurements (15–20%) (Berzigotti, 2017).
Augustin et al. proposed that the expanded Baveno criteria
(LS < 25 kPs and platelet count > 110,000/µl) may outperform
the original Baveno criteria since it spares 40% of variceal
screening endoscopies with a missing VNT rate of 1.6%
(Augustin et al., 2017). Since, multiple studies attempted
to validate these criteria with various success (Petta et al.,
2018; Calvaruso et al., 2019; Dajti et al., 2019; Moctezuma-
Velazquez et al., 2019; Tosetti et al., 2019a). However we must
be aware that the higher SER with the application of the
expanded Baveno criteria may be associated with an increased
number of missed VNTs (i.e., false negative cases in the 2
× 2 diagnostic table) because the negative predictive value
of the criteria is dependent on the pre-test probability of
VNTs (i.e., a more severe liver disease with higher VNT rate
will be associated with a lower negative predictive value of
the criteria).
CONCLUSIONS
Implications for Practice
Low missed VNT rate of Baveno criteria suggests that only
a minority of cases are misclassified who miss receiving
prophylactic treatment for variceal bleeding. Missed VNTs
account for 1–7.5 cases of 1,000 EGDs among cACLD patients.
The lower the prevalence of VNTs, the fewer VNTs are missed;
therefore, our results support the application of Baveno criteria
among cACLD patients. However, the criteria remain safe with
lower efficacy among cCLD patients irrespective of LS. Chance
of misclassification can be minimized by annually repeated
transient elastography performed by the same experienced
operator and platelet count assessment that could indicate
endoscopy on time (De Franchis, 2015; Perazzo et al., 2015). Our
meta-analysis proves the safety of Baveno criteria in ruling out
VNTs among cACLD patients while they help avoid one-third
of screening variceal endoscopies. We found that Baveno criteria
are applicable in HCV- and HBV-related liver disease and ALD,
and also in NAFLD, but further studies are needed to validate
these results.
Implications for Research
Accuracy metrics should be considered surrogate endpoints.
A randomized controlled trial with hard outcomes, such as
mortality and variceal bleeding, providing definitive proof of
safety, and effectivity of decision-making by Baveno criteria is
warranted. We also emphasize the need for finding further non-
invasive tests predicting VNT, not only to increase the number of
spared endoscopy but also for patients who are lacking reliable LS
and, consequently, where Baveno criteria cannot be applied.
In conclusion, our meta-analysis supports the application of
Baveno criteria in cACLD to exclude VNTs, saving financial
assets for health care by reducing the number of unnecessary
screening endoscopies by 32.8%. Addition of serological or
radiological markers to Baveno criteriamay improve the accuracy
of diagnosing varices. Although sparing one-third of EGDs seems
cost-effective, application of Baveno criteria still suffers from
a high rate of unnecessary endoscopies (442.5–560.4 cases per
1,000 EGDs). One possible option to reduce this number is
changing the cut-off values (e.g., the extended Baveno criteria,
risking an increasing missed VNT rate) (Bae et al., 2018) or
combination of LS and platelet count with other diagnostic
modalities, such as serum fibrosis markers or spleen diameter
measured by ultrasound (Abraldes et al., 2016).
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